Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

Vanda Pharmaceutical (VNDA) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart


See More
  • Market Capitalization, $K 676,780
  • Shares Outstanding, K 43,280
  • Annual Sales, $ 109,930 K
  • Annual Income, $ -39,870 K
  • 36-Month Beta 1.43
  • Price/Sales 6.16
  • Price/Book 5.16

Price Performance

See More
Period Period Low Period High Performance
14.90 +7.38%
on 12/07/16
17.60 -9.09%
on 11/25/16
-0.35 (-2.14%)
since 11/09/16
13.55 +18.08%
on 11/04/16
18.00 -11.11%
on 09/22/16
+0.16 (+1.01%)
since 09/09/16
6.91 +131.55%
on 02/11/16
18.00 -11.11%
on 09/22/16
+7.17 (+81.20%)
since 12/09/15

Most Recent Stories

More News
Horizon (HZNP) Stock Sinks, Friedreich's Ataxia Study Fails

Horizon Pharma (HZNP) has decided to discontinue the development of Actimmune for Friedreich's ataxia after a phase III study failed to meet key endpoints.

AstraZeneca (AZN) Presents Tagrisso Data at Medical Meeting

AstraZeneca plc (AZN) presented positive data from a randomized phase III study (AURA3) on its lung cancer drug Tagrisso at a lung cancer conference in Vienna, Austria.

Sage Therapeutics Stock Up on SAGE-547 Regulatory Update

Sage (SAGE) announced expedited development plan on SAGE-547 following receipt of formal meeting minutes from a breakthrough therapy meeting with the FDA.

Theravance Stock Up on Fast Track Status for Velusetrag

Theravance (TBPH) received Fast Track status from the FDA for velusetrag for idiopathic and diabetic gastroparesis.

Bristol-Myers Reports Data from Opdivo Combination Studies

Bristol-Myers (BMY) presented multiple data from Opdivo combination studies.

GW Pharma (GWPH) Posts Narrower-than-Expected Q4 Loss

GW Pharmaceuticals (GWPH) reported a narrower-than-expected loss of 89 cents per share in the fourth quarter of fiscal 2016 (ended Sep 30, 2016).

Novo Nordisk Files Regulatory Application for Semaglutide

Novo Nordisk (NVO) submitted regulatory application for semaglutide in both the U.S. and the EU for the treatment of adults with type II diabetes.

Acceleron, Celgene Present Myelodysplastic Syndromes Data

Acceleron (XLRN) and Celgene (CELG) announced updated data from the ongoing phase II studies on luspatercept in myelodysplastic syndromes patients.

Alnylam Reports Positive Data on Fitusiran, Givosiran

Alnylam (ALNY) announced new positive data from an ongoing phase II OLE study on fitusiran for the treatment of patients with hemophilia A or B, without inhibitors.

Pfizer (PFE) Presents Favorable Data on Leukemia Candidate

Pfizer Inc. (PFE) announced new positive data from a randomized phase II study on its investigational candidate glasdegib (PF-04449913) for the first-line treatment of patients with acute myeloid leukemia...

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Average.

See More

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Support & Resistance

2nd Resistance Point 16.53
1st Resistance Point 16.22
Last Price 15.95
1st Support Level 15.32
2nd Support Level 14.73

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.